Analyst Price Targets — CLLS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 20, 2025 10:45 am | Nick Abbott | Wells Fargo | $4.00 | $3.98 | TheFly | Cellectis price target raised to $4 from $3 at Wells Fargo |
| October 17, 2025 9:23 am | Gena Wang | Barclays | $8.00 | $4.52 | TheFly | Cellectis price target raised to $8 from $4 at Barclays |
Latest News for CLLS
NEW YORK, 13 avr. 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa plateforme pionnière d'édition de génome pour développer des thérapies innovantes pour le traitement de maladies graves, met en évidence aujourd'hui l'analyse intermédiaire de futilité communiquée par Allogene Therapeutics, Inc.
NEW YORK, April 13, 2026 (GLOBE NEWSWIRE) -- Cellectis (or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today highlights the interim futility analysis announced by Allogene Therapeutics, Inc. (“Allogene”) from Allogene's sponsored pivotal ALPHA3 trial evaluating cema-cel in…
(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of General Regulation of the French financial markets authority)
Cellectis S.A. (CLLS) Q4 2025 Earnings Call Transcript
NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today provided financial results for the fourth quarter and full year 2025, ending December 31, 2025 and provided a business update.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for CLLS.
Senate Trading
No Senate trades found for CLLS.
U.S. House Trading
No House trades found for CLLS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.